New Double-Action antibody shows promise against Hard-to-Treat cancers

NCT ID NCT04886271

Completed Disease control Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. The main goal was to see how many patients' tumors shrank or disappeared, and to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HX009 (a bifunctional antibody that targets CD47 and PD-1 proteins on cancer cells)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have not responded to standard therapies.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to larger populations. The drug may not shrink tumors or could cause side effects like immune-related inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

Shenzhen, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.